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Abstract
Background: In a cohort of patients with newly diagnosed psoriatic arthritis (PsA) who received usual care, we
investigated the impact of time elapsed to minimal disease activity (MDA) on health-related quality of life (HRQoL),
work productivity, and radiographic damage throughout the first year after diagnosis.
Methods: Data collected in the Dutch southwest early PsA cohort (DEPAR) study were analyzed. These three-
monthly data encompassed disease activity, HRQOL was measured with the Short Form 36 (SF36) Physical
Component Scale (SF36-PCS) and Mental Component Scale, and productivity was measured with the Productivity
Cost Questionnaire. Radiographic damage was scored at baseline and at 12 months with the PsA-modified Sharp/
van der Heijde score. Patients were classified by time to MDA as in early (within 3 months), late (at 6–12 months),
and never MDA in the first year.
Results: We included 296 patients who had had their 1-year outpatient visit (mean age 51 years, 53% male). Ninety-
six (32%) were classified as early MDA, 78 (26%) as late MDA, and 98 (33%) as never MDA. Data of 24 patients (8%)
were missing. SF36-PCS and productivity scores improved after gaining MDA, but remained low in never MDA
patients. At 1 year, SF36-PCS and productivity scores were similar in early and late MDA patients. Radiographic
progression rate was low and similar in all groups.
Conclusion: Gaining MDA was associated with considerable improvement in HRQoL and functioning, irrespective
of time to first MDA. In the one third of patients not in MDA in the first year, the disease had a substantial health
impact.
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Background
Psoriatic arthritis (PsA) is a chronic inflammatory dis-
ease presenting with arthritis, enthesitis, spondylitis,
dactylitis, and psoriasis [1]. As in other rheumatic dis-
eases, chronic inflammation leads to progressive joint
damage, increased disability, and reduced life expectancy
[2–4]. Treatment with disease-modifying antirheumatic
drugs (DMARDs) can alleviate this inflammation and
prevent these complications [5, 6]. Better clinical, func-
tional, and structural outcomes have been achieved with
the use of treat-to-target strategies in patients with
rheumatoid arthritis [7]. This implies that treatment
is intensified until a target of low disease activity is
reached. This strategy has been recommended in the
treatment of PsA as well [8], although as yet there is
no consensus of which target to use. Minimal disease
activity (MDA) is one of the proposed treatment tar-
gets in PsA.
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MDA is assumed to have been reached when at least
five out of seven PsA remission criteria are met [9]. In
previous cross-sectional studies, a state of MDA was
strongly related with better functioning and health-
related quality of life (HRQoL) [10–12]. Longitudinal
studies confirming these findings are lacking. We need
more information on how the state of MDA is related to
long-term improvement in disability and whether
achieving MDA early after the diagnosis results in better
outcomes than achieving MDA at a later stage.
We investigated the impact of time elapsed from diag-
nosis to MDA on HRQoL, productivity, and radio-
graphic damage at 1-year follow-up in a cohort of
patients newly diagnosed with PsA and receiving usual
care. We established if patients had reached MDA early,
late, or never in the first year after diagnosis and how
their HRQoL, work productivity, and radiographic dam-
age was throughout the first year after diagnosis.
Methods
Patients and setting
We used data collected in the Dutch southwest Early
Psoriatic Arthritis cohoRt (DEPAR) study, of which de-
tails are described elsewhere [11]. Patients with a new
diagnosis of PsA are eligible to participate if they have
not yet received treatment with DMARDs for PsA. Writ-
ten informed consent was obtained from all participants
according to the Declaration of Helsinki. The study was
approved by the medical research ethics committee of
the Erasmus University Medical Center Rotterdam, the
Netherlands (MEC-2012-549). We analyzed data col-
lected between August 2013 and June 2017 and excluded
patients with baseline visits after June 2016.
Data collection
In the first year, data are collected every 3 months. Dur-
ing the study visits, trained research nurses collect clin-
ical data, including swollen and tender joint count (resp.
SJC 66 and TJC 68 joints), enthesitis at clinical examin-
ation (Leeds Enthesitis Index, LEI [13]), and psoriasis
(Psoriasis Area and Severity Index, PASI [14]). Patients
complete multiple questionnaires shortly before or after
their visits. For this analysis, we used data on the Short
Form 36 (SF36, [15]), the Health Assessment Question-
naire (HAQ, [16]), the Productivity Cost Questionnaire
(PCQ, [17]), and patient-reported visual analog scale
(VAS) scores for global and pain.
Minimal disease activity
MDA state was determined at each visit within the first
year. A state of MDA was assumed to have been reached
if five of seven MDA criteria were met: SJC ≤ 1, TJC ≤ 1,
LEI ≤ 1, PASI ≤ 1, global VAS ≤ 20 mm, pain VAS ≤ 15
mm, HAQ ≤ 0.5 [9]. In case of missing data of some
criteria, MDA status was ascertained irrespective of the
missing information (e.g., fulfilling five criteria and miss-
ing two criteria). If missing information could alter the
MDA status (e.g., fulfilling four criteria and missing
two), we considered MDA status missing. If MDA status
before and after a missing visit was equal (i.e., both
MDA or both no MDA), we assumed that MDA status
at the missing visit was equal to that state. Achieving
MDA was classified as early if it had been achieved at
baseline or at 3 months, as late if it was first achieved
after 3 months but within the first year, and as never if it
was not achieved in the first year. In addition, achieving
MDA was classified as sustained if patients remained in
MDA until their 1-year follow-up visit.
Outcomes
Patients self-reported HRQoL with the SF36 Physical
Component Scale (PCS) and Mental Component Scale
(MCS). Work productivity was assessed with the PCQ,
relating to work and productivity in the 4 weeks preced-
ing the study visit. We determined employment status,
absence, working hours, and productivity loss at work
and at home throughout the first year. The actual num-
ber of productivity hours per week was calculated by
subtracting hours of absence and productivity loss at
work in hours from the total number of self-reported
working hours.
Radiographs of the hand and feet obtained at baseline
and after 1 year were scored twice, by three trained as-
sessors separately. The assessors were blinded to the pa-
tient’s identity and clinical data and scored the images in
chronological order. According to the PsA-modified
Sharp/van der Heijde score (PsA-SHS), erosions and
narrowing of hand and feet joints were scored with a
maximum of 320 for erosions and 208 for joint space
narrowing [18]. Differences in absolute score above 2
and differences in progression were discussed by the two
assessors. Regarding the inter-rater reliability, the kappa
statistics was 0.79 with absolute agreement of 99%. For
each patient, the mean of two scores was calculated. The
smallest detectable difference (SDD) was 0.27. Progres-
sion was defined as a mean increase in PsA-SHS in the
first year exceeding the SDD.
Statistical analysis
Differences in characteristics between MDA groups were
tested with ANOVA tests and subsequent t-tests for
continuous data and chi-squared tests for categorical
data. The effect of time to MDA on outcomes after
1 year was analyzed with multiple linear regression ana-
lysis with outcomes SF36-PCS, SF36-MCS, and product-
ivity. The association of time to MDA (early vs. late,
early vs. never and late vs. never) with the outcome was
corrected for baseline score SF36 or productivity score,
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age, gender, symptom duration, DMARD use, erosive
disease at baseline, and baseline disease activity (baseline
SJC, TJC, LEI, PASI, VAS global, VAS pain, and HAQ).
In the subset of patients using DMARDs in the first year,
the same analysis was performed with the added vari-
ables time to start and duration of DMARD therapy.
Linear mixed effects models were used to compare pro-
gression of outcomes between the three groups and to
account for missing data. Baseline outcome score, base-
line disease activity and erosive disease, age, gender,
symptom duration, DMARD use, time, MDA group, and
interaction between time and MDA group were included
in the fixed-effects part. Random intercepts were
included in the random-effects part; an optimal
random-effects structure was chosen based on the
Akaike information criterion. Analyses were performed
in STATA 15.1 and R-3.4.2.
Results
In July 2017, 296 patients had had their 1-year visit and
268 (92%) could be assigned an MDA category. The
mean age of the latter was 51.2 years (standard deviation
(SD) 14), 142 were male (53%), and the median
self-reported symptom duration was 1.0 years (interquar-
tile range (IQR) 0.4–2.7, Table 1). Ninety-four (35%) had
achieved MDA within 3 months (early MDA; 40 already
in MDA at baseline), 77 (29%) between 6 and 12months
(late MDA), and 97 (36%) were never in MDA during
the first year (never MDA). MDA state was sustained
until 1 year by 43 (48%) early MDA patients and 46
(52%) late MDA patients. Patients early in MDA were
significantly more often in MDA than patients late in
MDA (of 5 visits: mean 3.6 vs. 1.8, p < 0.01).
Age, gender, and symptom duration did not differ signifi-
cantly between groups (Table 1). Patients never in MDA
had significantly higher SJC, TJC, LEI, HAQ, PASI, and
VAS scores at baseline than patients in MDA (both early
and late). Patients late in MDA had significantly higher dis-
ease activity than patients early in MDA on all domains but
SJC and PASI. In the first year, DMARDs were prescribed
to 210 patients (78%): methotrexate to 197 patients (74%)
and biological therapy to 33 patients (12%).
Quality of life
The evolvement of the mean SF36-PCS and SF36-MCS
scores per group is shown in Fig. 1. The mean SF36-PSC
Table 1 Patient characteristics of MDA groups and of total study population
Early MDA (n = 94) Late MDA (n = 77) Never MDA (n = 97)
Age 50.1 ± 14 50.4 ± 13 52.8 ± 14
Male 57 (61) 41 (53) 44 (45)
Symptom duration in years 0.9 (0.2–2.4) 0.8 (0.3–1.5) 1.6 (0.4–4.1)
Disease activity at baseline
Swollen joint count (66) 1 (1–3) 3 (1–4) 2 (0–6)$
Tender joint count (68) 1 (0–3) 3 (2–7)* 5 (3–12)$
LEI 0 (0–0) 0 (0–1)* 1 (0–2)$
HAQ 0.13 (0.00–0.63) 0.63 (0.38–0.89)* 0.88 (0.63–1.38)$
PASI 1.5 (0.4–3.8) 2.3 (0.3–4.1) 3 (1.2–6.1)$
VAS global 21 (9–37) 46 (24–66)* 55 (40–70)$
VAS pain 17 (9–44) 47 (30–63)* 56 (44–74)$
Medication in first year
Any DMARD 62 (66) 63 (82)* 85 (88)$
Methotrexate 57 (61) 61 (79)* 79 (81)$
Sulfasalazine 8 (9) 14 (18) 23 (24)$
Hydroxychloroquine 4 (4) 11 (14) 8 (8)
Leflunomide 8 (9) 8 (10) 17 (18)
Prednisone (oral) 13 (14) 14 (18) 18 (19)
Prednisone (intramuscular injection) 11 (12) 21 (27)* 34 (35)$
Prednisone (intra-articular injection) 29 (31) 27 (35) 15 (15)$
Biological 5 (5) 12 (16)* 16 (16)
Results shown as mean ± standard deviation, n (%) or median (interquartile range). *Early vs. Late MDA and $MDA vs. Never MDA p < 0.05 of t-test (continuous
data) or chi-squared (categorical data). MDA minimal disease activity, Early MDA MDA within 3months, Late MDA MDA between 3 and 12, Never MDA no MDA
within first year. LEI Leeds Enthesitis Index, HAQ Health Assessment Questionnaire, PASI Psoriasis Area and Severity Index, VAS visual analogue scale, DMARD
disease-modifying antirheumatic drug
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score at 1 year was similar in the early and late MDA
groups and was better than that in the never MDA
group. Linear regression analysis of the SF36-PCS score
at 1 year, correcting for baseline score, gender, age,
symptom duration, DMARD use, erosive disease at base-
line, and baseline disease activity, showed that SF36-PSC
scores were significantly lower in the never MDA group
than in the early MDA group (β − 6.22, 95% CI − 9.92,
− 2.51) and the late MDA group (β − 7.86, 95% CI −
11.52, − 4.21, Table 2). At baseline, SF36-PCS scores in
the early MDA group were higher than those in the late
MDA group and the never MDA group and had in-
creased earlier than in the late MDA group. Linear
mixed model analysis confirmed a difference in evolu-
tion over time between the three groups (likelihood ratio
test (LRT) of interaction between time and group: 34.5,
p < 0.0001). Results in the subgroup of patients using
DMARDs were similar in analyses correcting for dur-
ation of DMARD therapy and time to start DMARD
therapy. The SF36-MCS scores significantly differed be-
tween the three groups at baseline and remained fairly
stable over time, which was confirmed by a
non-significant interaction term of time and MDA in
the linear mixed model analysis (LRT 1.73, p = 0.42). At
1 year, the SF36-MCS scores were significantly higher in
the early MDA group than in the never MDA group (β
− 6.11, 95% CI − 9.51, − 2.70, Table 2).
Productivity
At 1 year, 207 of the 250 patients who had completed
productivity questionnaires (83%) were in the employ-
able age. Of those, 153 (74%) were actually employed: 64
(87%) early MDA, 48 (76%) late MDA, and 41 (60%)
never MDA patients (Table 3). Of the 53 unemployed
subjects, 7 patients had become unemployed since diag-
nosis (1 early MDA, 3 late MDA, and 3 never MDA)
and 46 were already unemployed at baseline. At 1 year, 8
reported long-term sick leave (1 late MDA (2%) and 7
never MDA (17%)) and 21 short-term sick leave in the
past 4 weeks (10 early MDA (16%), 5 late MDA (11%),
and 6 never MDA (18%)). Work productivity loss in the
past 4 weeks was reported most often by never MDA
patients (71%, vs. early MDA 27% and late MDA 30%).
The mean productivity loss in patients with productivity
Fig. 1 HRQoL and productivity outcomes in the first year per MDA group. SF36: Short Form 36, PCS: Physical Component Scale, MCS: Mental
Component Scale, MDA: minimal disease activity. Results shown as mean and 95% confidence interval
Table 2 Linear regression models outcomes after 1 year
β (95% CI)
SF36-PCS
Early vs. Late MDA 1.64 (−1.63, 4.91)
Early vs. Never MDA −6.22 (−9.92, −2.51)
Late vs. Never MDA −7.86 (− 11.52, −4.21)
SF36-MCS
Early vs. Late MDA −2.83 (−6.14, 0.06)
Early vs. Never MDA −6.11 (−9.51, − 2.70)
Late vs. Never MDA −3.07 (− 6.16, 0.02)
Hours productivity loss
Early vs. Late MDA 0.78 (−5.63, 7.20)
Early vs. Never MDA −6.59 (−14.55, 1.37)
Late vs. Never MDA −7.38 (−14.38, −0.38)
Early MDA MDA within 3months, Late MDA MDA between 3 and 12 months,
Never MDA no MDA within first year, SF36 Short Form-36, PCS Physical
Component Scale, MCS Mental Component Scale. All analyses corrected for
baseline score, gender, age, symptom duration, use of disease-modifying
antirheumatic drugs, erosive disease at baseline, and baseline disease activity
(SJC, TJC, LEI, PASI, VAS global, VAS pain and HAQ)
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loss did not differ significantly between the groups.
Mean productivity at work of employed patients during
the first year is shown in Fig. 1. Productivity increased in
the late MDA group from a baseline level similar to that
in the never MDA group, to a level similar to that in the
early MDA group at 1-year follow-up. This was con-
firmed in the linear regression analysis (Table 2): total
productivity at work was significantly lower at 1 year in
the never MDA group than in the late MDA group (β −
7.38, 95% CI − 14.38, − 0.38). The difference in evolution
over time between the three groups was confirmed in a
linear mixed model analysis (LRT of interaction between
time and group 6.93, p = 0.032).
Radiological damage
Mean PsA-SHS was 3.5 (SD 10; 16 missing) at baseline:
the erosion score was 1.4 (SD 4.6) and the narrowing
score was 2.2 (SD 5.9). Mean progression in 1 year was
0.38 (SD 1.4; 31 missing). Both baseline and progression
scores did not differ significantly between the groups.
The PsA-SHS score had progressed in 34 patients (14%):
8 in the early MDA group (10%), 11 in the late MDA
group (17%), and 15 in the never MDA group (17%).
Twenty-seven of the 34 patients with progression in the
first year had already radiological damage at baseline.
Discussion
In this cohort of newly diagnosed PsA patients receiving
usual care, HRQoL and productivity throughout the first
year after diagnosis were best in those who reached
MDA early. At 1 year, however, patients late in MDA
had achieved similar levels of HRQoL and work prod-
uctivity as patients in the early MDA group, even though
they were significantly shorter in MDA. Patients never
in MDA had significantly lower scores throughout the
first year and this remained so at their 1-year visit.
Radiological progression did not differ in the first year
between the three groups.
In a previous cross-sectional analysis in our cohort,
having reached a state of MDA was related to better
HRQoL and functioning [11]. Other studies found simi-
lar results [10, 12]. The present study, however, is the
first to address associations between gaining MDA and
improvement of HRQoL and functioning over time. We
found that gaining MDA, irrespective of the time
elapsed since diagnosis, was associated with subsequent
improvements of HRQoL and functioning over time. A
slightly longer period of high disease activity was not as-
sociated with irreversible effects on HRQoL, functioning,
or radiology after 1 year.
Still, one third of all patients was not able to achieve
MDA in the first year and also did not show improve-
ment in HRQoL and functioning. Even after correcting
for baseline differences in disease activity and HRQoL
scores, these patients’ SF36-PCS scores were 8 points
lower than in the rest of the population. While patients
in the late MDA group showed a clinically important
improvement [19], patients in the never MDA group did
not. Furthermore, almost all patients in the latter group
reported some form of impact on their work: becoming
unemployed, sick leave, or significant productivity loss at
work. Thus, the impact of disease is severe and wide-
spread in patients who do not achieve MDA. Interest-
ingly, the baseline values of patients in the never MDA
group did not differ much from those of patients in the
late MDA group. If it were possible to predict achieve-
ment of MDA, patients at risk of not achieving MDA
could be offered more intensive monitoring and earlier
escalation of therapy.
Although analysis revealed a relation between time to
MDA and HRQoL and productivity throughout the first
year, a difference in radiological progression between the
three groups was not shown. We assume that this is the
consequence of a lack of power resulting from the
strong association with damage present at baseline and
the low prevalence of progression of 14%. Several causes
for this low prevalence can be proposed. First, the 1-year
Table 3 Productivity outcomes after 1 year in MDA groups and in total study population
Early MDA (n = 91) Late MDA (n = 73) Never MDA (n = 86)
Employable age 74 (81) 64 (88) 69 (80)
Employed 64 (87) 48 (76) 41 (60)
Working hours per week 36 (33–39) 35 (31–38) 32 (28–37)
Long-term absence 0 (0) 1 (2) 7 (17)
Short-term absence 10 (16) 5 (11) 6 (18)
Productivity loss at work 17 (27) 14 (30) 24 (71)
Hours per week productivity loss at work in patients with productivity loss 6.7 (4–10.5) 7.6 (4.8–16.8) 7.9 (4.5–18.9)
Total productivity at work 32 (29–35) 29 (25–34) 19 (14–25)
Results shown as mean (95% confidence interval) or n (%) unless otherwise indicated. Early MDA MDA within 3months, Late MDA MDA between 3 and 12, Never
MDA no MDA within first year, IQR interquartile range. Total productivity = hours per week - absence - productivity loss at work, calculated in mean per week over
past 4 weeks
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follow-up was too short to demonstrate differences in
this population. Second, radiological evaluation com-
prised assessment of hand and feet joints only, which
are not necessarily the joints most often affected in for
example oligoarthritis or monoarthritis patients. Third,
disease activity in this usual care population at time of
inclusion was lower than that in, for example, trial popu-
lations, for which higher progression rates have been re-
ported [20, 21].
In this observational cohort, all patients with a new
diagnosis of PsA were eligible to participate. They all re-
ceived usual clinical care and their outcomes are there-
fore reflective of current clinical care. Their treatment
differed, however, as treatment was not protocolized.
This heterogeneity of treatment could be a confounder
of the relation between time to MDA and outcomes.
However, as choice of treatment was associated with dis-
ease activity, correcting for baseline disease activity and
use of DMARDs in the analyses reduced a substantial
part of the confounding. Further, correcting for time to
starting DMARD therapy and time on DMARD therapy
did not alter the effects of MDA group on the outcomes.
Unmeasured confounding by treatment could be present
but likely has not affected our conclusion, given the
small differences in treatment between the three groups.
This study has several strengths and limitations. First,
the population studied reflects the population of PsA pa-
tients receiving usual care. Thus, our conclusions are
better generalizable than those from trials or biological
registries, where patient selection bias might have oc-
curred. Second, reliability of the clinical data collection
is ensured because data were collected by research
nurses in a standardized manner during dedicated study
visits. As a limitation, this could however introduce dis-
crepancies between disease activity and treatment strat-
egy, as the latter is determined by physicians based on
their own assessment of disease activity, unaware of
the nurse’s assessment. We, therefore, cannot exclude
incomplete correction for confounding by disease ac-
tivity, although we also corrected for DMARD ther-
apy. Another limitation is the heterogeneity of
treatment strategies, as discussed above. There is a
possibility of selective drop-out of patients. It could
well be that patients with early MDA are discharged
from clinical care and are less likely to complete
follow-up and be included in our 1-year analysis. As
a consequence, the rates of MDA and productivity
may be underestimated, in which case the true effect
of MDA on productivity is even larger. Last, in our
analysis of data after 1 year, we were not able to
show a difference between groups in MDA within
1 year on outcomes at 1 year, but we might see a dif-
ference in future analyses of patients later in MDA
and with longer follow-up.
Conclusion
In conclusion, patients who gained MDA in the first year
after diagnosis showed considerable improvement in
HRQoL and functioning, irrespective of the time elapsed to
the first MDA episode. In one third of patients who did not
gain MDA in the first year after diagnosis, the impact of
disease remained as substantial as at the time of diagnosis.
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